OBJECTIVE: To evaluate two commercial stool tests for detection of secretory IgA antibodies against gliadin and human tissue transglutaminase for diagnosis of coeliac disease in children with symptoms. SETTING: Tertiary care children's hospital. PARTICIPANTS: Coded stool samples from 20 children with newly diagnosed coeliac disease and 64 controls. Six children with coeliac disease had stool tests every two weeks for three months after starting a gluten-free diet. MAIN OUTCOME MEASURES: Secretory IgA antibodies against gliadin and human tissue transglutaminase in stool samples, determined in duplicate by using recommended cut-off limits. RESULTS: Sensitivity of faecal antibodies against human tissue transglutaminase was 10% (95% confidence interval 1% to 32%), and specificity was 98% (91% to 100%). For antibodies against gliadin, sensitivity was 6% (0% to 29%) and specificity was 97% (89% to 100%). Optimisation of cut-off limits by receiver operating characteristic analysis and use of results of both tests increased sensitivity to 82%, but specificity decreased to 58%. All follow-up stool tests remained negative, except for two positive anti-gliadin results in one patient, six and 10 weeks after the gluten-free diet was started. CONCLUSIONS: Neither stool test was suitable for screening for coeliac disease in children with symptoms.
OBJECTIVE: To evaluate two commercial stool tests for detection of secretory IgA antibodies against gliadin and humantissue transglutaminase for diagnosis of coeliac disease in children with symptoms. SETTING: Tertiary care children's hospital. PARTICIPANTS: Coded stool samples from 20 children with newly diagnosed coeliac disease and 64 controls. Six children with coeliac disease had stool tests every two weeks for three months after starting a gluten-free diet. MAIN OUTCOME MEASURES: Secretory IgA antibodies against gliadin and humantissue transglutaminase in stool samples, determined in duplicate by using recommended cut-off limits. RESULTS: Sensitivity of faecal antibodies against humantissue transglutaminase was 10% (95% confidence interval 1% to 32%), and specificity was 98% (91% to 100%). For antibodies against gliadin, sensitivity was 6% (0% to 29%) and specificity was 97% (89% to 100%). Optimisation of cut-off limits by receiver operating characteristic analysis and use of results of both tests increased sensitivity to 82%, but specificity decreased to 58%. All follow-up stool tests remained negative, except for two positive anti-gliadin results in one patient, six and 10 weeks after the gluten-free diet was started. CONCLUSIONS: Neither stool test was suitable for screening for coeliac disease in children with symptoms.
Authors: Antonio Picarelli; Luigi Sabbatella; Tola Marco Di; Cello Teresa Di; Stefania Vetrano; Maria Cristina Anania Journal: Am J Gastroenterol Date: 2002-01 Impact factor: 10.864
Authors: A Tosco; R Aitoro; R Auricchio; D Ponticelli; E Miele; F Paparo; L Greco; R Troncone; M Maglio Journal: Clin Exp Immunol Date: 2013-01 Impact factor: 4.330
Authors: A Tosco; R Auricchio; R Aitoro; D Ponticelli; M Primario; E Miele; V Rotondi Aufiero; V Discepolo; L Greco; R Troncone; M Maglio Journal: Clin Exp Immunol Date: 2014-09 Impact factor: 4.330
Authors: Alberto Rubio-Tapia; Ivor D Hill; Ciarán P Kelly; Audrey H Calderwood; Joseph A Murray Journal: Am J Gastroenterol Date: 2013-04-23 Impact factor: 10.864
Authors: Sheeana Gangadoo; Piumie Rajapaksha Pathirannahalage; Samuel Cheeseman; Yen Thi Hoang Dang; Aaron Elbourne; Daniel Cozzolino; Kay Latham; Vi Khanh Truong; James Chapman Journal: Int J Mol Sci Date: 2021-02-17 Impact factor: 5.923